Aim of the study: To study the effect of prescribing inhibitors of sodium glucose cotransporter type 2 (iSGLT-2) and inhibitors of dipeptidyl peptidase-4 (iDDP-4) on the parameters of carbohydrate metabolism in patients with type 2 diabetes.
Materials and methods: A prospective study included 80 patients with type 2 diabetes. The average age was 52.7 ± 3.78 years; diabetes experience - 8 years; BMI-30 ± 0.17; Hb1C-9.2 ± 0.4%; fasting glycemia –10.2 mmol/; eGFR-78 ml/min; TG-2.7 ± 0.44; total cholesterol-3.4 ± 0.72; MAU 32 ± 0.125. The patients were divided into 2 groups: group 1 - 30 patients with DN with impaired renal function and 30 patients with diabetic nephropathy without renal dysfunction in the presence of metformin + iSGLT- 2; 2 group of 30 patients with impaired renal function and 30 patients with diabetic nephropathy without impaired renal function on the background of metformin + iDPP-4.
Results: The study of the effect of the inclusion of drugs iSGLT-2 (group 1) and iDPP-4 (group 2) showed a positive dynamics of carbohydrate metabolism indicators in patients with type 2 diabetes. So if the initial indicators in the groups were comparable in terms of glycemic control indicators, then by the 3rd month of treatment there was a significant decrease in HbA1c in the 1st group of patients in relation to the 2nd group. The result of the correction performed within 3 months was the achievement of the state of compensation in the 1st group in 36.7%, and in the 2nd group in 28.3%, 48.3% of the patients of the 1st group were brought into the state of sub compensation and 31.7 % of patients of the 2nd group.
Conclusion: On the combination of metformin and INGLT-2, a larger number of patients managed to achieve the set goals of therapy with a lower risk of overt hypoglycemia, then this combination should be considered not only more effective.
The study aimed to assess the functional state of the kidneys and to study the relationship of I/D polymorphism of the ACE gene with the stage of chronic kidney disease in children and adolescents of the Uzbek population with type 1 diabetes according to the new recommendations of K/DOQI (2012). We examined 120 children and adolescents with type 1 diabetes. Clinical, biochemical and genetic studies have been carried out. The study revealed that children with diabetes in the stage of compensation (НbА1с ≤7.5%) have CKD stages II (28.6%) and III (4.8%). The use of the new classification K/DOQI (2012) reveals a decrease in kidney function at earlier stages, in 61.9% of children and adolescents with type 1 diabetes, even at the NAU stage, a GFR of 80.6 ± 7.5 ml/min/1.73m2, which corresponds to stage II of CKD and 16.7% have a GFR of 45.1 ± 9.5 ml/min/1.73m2, which corresponds to stage III of CKD. Also, 28.6% of children and adolescents at the MAU stage have CKD II, 75.0% of CKD stage III, respectively. ACE I/D polymorphism is a molecular genetic marker of susceptibility to the development of CKD type 1 diabetes in children and adolescents.
The aim of the study. To study the clinical characteristic and quality of life of the patients with type 2 diabetes mellitus.
Material and methods. We examined and examined a total of 80 patients with diabetic nephropathy on program hemodialysis for the period from January 1, 2018, to January 1, 2020.
Results. In this article, the authors analyze 80 cases of diabetic nephropathy that were on programmed hemodialysis. Of these, 32 women, 48 men. The results also confirm the literature that patients with type 2 diabetes mellitus have a low quality of life indicators before hemodialysis.
Conclusions. A questionnaire to determine the quality indicators - WHOQOL-BREF, MMSE, Hamilton depression scale are the most sensitive and informative to determine the quality of life in patients with chronic kidney disease.
Diabetes mellitus is a common endocrine disease, which belongs to the risk factors for the development of changes in periodontal tissues. The presence of diabetes mellitus in patients can cause the development of structural and functional changes in the maxillofacial area, and also increase the risk of changes in the tissues of the parodontium. At the same time, the nature of these changes and the degree of influence of diabetes mellitus on the state of the tissues of the parodon are 46 insufficiently studied. In this regard, it is necessary to pay great attention to this problem in order to provide timely assistance to these patients in order to avoid rather serious complications
The number of patients with diabetes mellitus in the Andijan region who were registered according to endocrinologists from 2000 to 2015 increased almost fourfold from 26,000 to more than 110,000 in 2016 (14). This also shows that the number of patients with various purulent-necrotic complications of diabetes mellitus also increases proportionally, in addition, there is an increase in patients with severe purulent-septic complications of these processes, with widespread, deep purulent-necrotic fasciitis [3]. Of patients in the department of surgical infection of the ASMI clinic, patients with purulent-necrotic complications of diabetes mellitus account for almost 78%, which indicates a significant increase in the number of these patients. This tendency continues and goes up every year. According to the WHO, by 2030 every 15 people will have diabetes, and by 2050 this figure will be equal to every 6 people.
Эффективность препарата квадроприл проверяли у 47 больных сахарным диабетом I и П типа с сосудистыми осложнениями. Оценивали функциональное состояние почек, гемодинамические показатели и микроциркуляцию бульбарной конъюнктивы глаз. Препарат оказывал выраженное гипотензивное действие, улучшал нитрацию клубочков, влияя на инсулинорезистентность, способствовал значительному снижению микроциркуляции и не имел побочных эффектов.